text:
Tag: Tesla
Medical Marijuana (Stand Up Comedy)
4/20 Roundup: How Brands Are Marking Marijuana's Increasingly Mainstream Holiday – Adweek
The origin story has gone from urban legend to the Oxford dictionary: A group of high school stoners in Northern California in the '70s birthed the concept of 4/20, and their friendship with the Grateful Dead helped turn an afternoon burnout activity into a legitimate movement. Now 4/20 is an unofficial national holiday, gathering steam as states across the country continue to legalize marijuana for recreational sales. There aren't any Hallmark cards to commemorate it but there are plenty of ways to celebrate, from the High Times Cannabis Cup to the Mile High Block Party and Snoop Dogg's Wellness Retreat to far too many Cheech & Chong movie marathons to count. More than 10,000 Mary Jane-loving people are expected to gather in San Francisco's Golden Gate Park. Pepsi, HBO, Denny's, Carl's Jr, Ben & Jerry's and plenty of other marketers have used their social channels to reefer, um, refer to cannabis culture.
MedMen, the largest marijuana retailer in Southern California, recently launched its most extensive ad campaign ever, and other endemic brands are predictably hot boxing the holiday. Lyft and Fox Searchlight have launched a joint promotion for Super Troopers 2, the follow-up to the goofball cop comedy from 2001 that went from micro-budget release to sleeper hit to cult classic. The new flick, a U.S.-versus-Canada border romp with plenty of ugly American references, opens Friday and comes from the original team, the Broken Lizard comedy troupe, with partial funding from an Indiegogo campaign. Lyft plucked all the main characters, who return as hapless Vermont State Troopers, for a shenanigan-filled PSA about driving while high. In markets where recreational sales are legal, Lyft created out-of-home ads and wild postings, and there's in-car swag like stickers, buttons and safety guides.
An in-app takeover allows users to opt into Super Troopers mode for Easter eggs and movie character cameos. TBS. On a more sober note, Full Frontal with Samantha Bee spent time this week promoting its #ReeferSanity grassroots program, aiming to pressure lawmakers into allowing U.S. veterans access to medical marijuana.
Keywords: ["high","Lyft","movie"]
Source: https://www.adweek.com/creativity/4-20-roundup-how-brands-are-marking-marijuanas-increasingly-mainstream-holiday/
elon musk: Elon Musk smokes weed, drinks whiskey on California comedian's show
Elon Musk sipped whiskey and smoked marijuana during a 2 1/2-hour podcast with California comedian Joe Rogan that touched upon everything from flame throwers and artificial intelligence to the end of the universe. Musk, 47, took one drag from what Rogan described as a joint containing tobacco mixed with marijuana, which is legal in California. A Tesla spokesperson in Germany wasn't immediately available to comment. The spot on one of the most popular podcasts in the U.S. marks Musk's first appearance in a public forum since he stunned the financial world last month with his short-lived effort to take Tesla private.
Just 17 days after tweeting that he had the funding and investor support secured to buy out some stockholders at $420 a share, the billionaire scrapped the idea without having made a formal proposal to the board. Along the way, Musk drew a subpoena from the Securities and Exchange Commission, which already had been scrutinizing the public pronouncements he's made regarding manufacturing goals and sales targets. Tesla and its CEO are now also facing a litany of lawsuits claiming market manipulation, including one filed Thursday by Andrew Left, the founder of Citron Research and prominent short seller. The episode also raised concern about Musk's health. The chairman and CEO of both Tesla and Space Exploration Technologies Corp., among other companies, gave an emotional interview to the New York Times in which he said friends were concerned about exhaustion.
The newspaper said two people familiar with the electric-car maker's board expressed concern about his workload and use of the prescription sleeping drug Ambien. Musk also told Rogan that running Tesla is the hardest of his several endeavors, describing the hardships of heading an auto manufacturer.
Keywords: ["Musk","Tesla","concern"]
Source: https://economictimes.indiatimes.com/magazines/panache/elon-musk-smokes-weed-drinks-whiskey-on-california-comedians-show/articleshow/65718057.cms
Ohio: Attend The Compassionate Alternatives Comedy Benefit – Weed News
Below is an event that I came across that sounds very cool. Compassionate Alternatives mission is to inform and empower patients, parents, caregivers, and medical professionals about the truths, science, and potential of medical cannabis. They develop and produce seminars and other educational programs to help parents, patients, caregivers, and other medical professionals understand the science and potential therapeutic benefits of medical cannabis. Visit compassionatealternatives.org to learn more. The event will begin with ticket complimentary refreshments and discussion about the benefits of cannabis medicine with Compassionate Alternatives.
CA will talk about their progress and mission they've been building in Ohio. The comedy entertainment will begin with Adam Smith hosting comedians Jordan Tolford, Gilli, Brooke Huffer, JR Junior, and headliner Brian Doney. This will be one of Brian Doney's last performances before moving to New York! We'll be wrapping things up with a jam session with Christian Foster. Grab a drink an kick back to some Fingerstyle jazz guitar after a fun evening with stand-up comedy and Compassionate Alternatives.
Have a great evening of entertainment while supporting a great cause!
Keywords: ["medical","Alternatives","cannabis"]
Source: https://www.weednews.co/ohio-attend-the-compassionate-alternatives-comedy-benefit/
'It's Simple. I'm Playing A Retired Boxer Who Is Growing Marijuana,' Mike Tyson Shops New Comedy TV Series
It might be too early to judge, but Mike Tyson's new cannabis-themed show sounds a lot like 'Disjointed' 2.0. The former heavy-weight boxing champion says he is shopping around a new TV series. The show is called 'Rolling With the Punches,' and will be loosely based on Tyson's own experiences a a marijuana grower and marketer, with Iron Mike himself in the leading role. The show will be shot and set on Tyson Ranch, a marijuana resort launched by the famed boxer back in June. Rob Hickman, Tyson's business partner, says former 20th Century Fox and Walt Disney Studios exec Joe Roth is producing the show, which should begin airing this spring.
Hopefully the show is picked up by somebody who isn't Netflix, since their track record with cannabis centrist programming hasn't been very good.
Keywords: ["Tyson","show","marijuana"]
Source: https://www.civilized.life/articles/its-simple-im-playing-a-retired-boxer-who-is-growing-marijuana-mike-tyson-shops-new-comedy-tv-series/
Weed is finally legal on October 17th! | 22 Minutes
A stoner looks at 80: Comedian, marijuana advocate Tommy Chong reflects on his career
LOS ANGELES – Yeah man, Tommy Chong says he always knew he'd live to see the day marijuana legalization would be sweeping the country. Not even in 2003 when Chong was imprisoned for nine months for conspiring to distribute handcrafted artisanal bongs the government declared drug paraphernalia. So much so that when the High Priest of Stoner Comedy turns 80 on Thursday – that's right, 80 – he expects his Chong's Choice brand of marijuana, available in legal dispensaries in several states, will be consumed in abundance at the parties his family is planning. Not that he was ever a heavy pot user, Chong says, just a consistent connoisseur. When no other hits followed, Motown dropped the group, and the Canadian-born Chong returned to Vancouver, British Columbia, where he ran a pair of strip clubs with his brother.
Motown had helped Chong obtain a green card, and the two headed to fame and fortune in Los Angeles. On a recent early morning, Chong answers the door for a photo shoot at his longtime home in the hills overlooking L.A.'s wealthy Brentwood section, arriving in gray jeans, sandals and a black T-shirt advertising the name of a Colorado cannabis dispensary he recently visited. As a photographer sets up, Chong polishes off a breakfast of oatmeal topped with sliced banana. Chong, whose father emigrated from China before World War II, mostly identifies culturally as Chinese, although he's equally proud of his Scotch, Irish and Native American ancestry from his mother's side. More than just a stoner comedian, he's been a passionate marijuana advocate for decades.
Before the pair's bitter 1980s breakup, Cheech and Chong dominated comedy for 15 years. Those efforts generally ended in angry, insult-laden exchanges until 10 years ago when Paris Chong intervened.
Keywords: ["Chong","years","Marin"]
Source: http://www.chroniclet.com/national-news/2018/05/24/A-stoner-looks-at-80-Comedian-marijuana-advocate-Tommy-Chong-reflects.html
Stoner Flicks: These Are The 21 Greatest '90s Movies Inspired By Weed
Today, new stoner comedies pop up in DVD rental boxes and on streaming video services with the ubiquity of medical dispensaries in just-legalized shopping districts. In retrospect, the ten years when alternative rock reigned and hip-hop soared-each fueled by weed fumes-also produced the stoner movie classics we talk about most when we talk about stoner movie classics. Director Richard Linklatter guides a soon-to-be all-star cast through the last day of high school in 1976. Doobs blaze in the Austin heat while a killer stoner rock soundtrack intoxicates all involved, end-to-end. As outrageous as the situations around our high heroes get, they never lose their hip-hop cool.
Their slapstick marijuana misadventures prove riotously funny, as do cameos by Snoop Dogg, Willie Nelson, Tommy Chong, Tracy Morgan, and Bob Saget. Jeff Bridges as The Dude may stand as stoner cinema's single most towering toke-it-up icon. The Coen brothers' brilliantly pot-bent take on LA film noir also makes clear how marijuana makes even the most crackpot capers come off as plausible-and hilarious. The director debuts himself as Silent Bob opposite Jason Mewes as his perma-stoned best bud, Jay, in the first of many big-screen crack-ups. What makes it stoner gold is Brad Pitt as Floyd, a high AF laid-back charmer forever clutching the sweet bong he crafted from a bear-shaped honey jar.
Billy Bob Thornton is a blast as a Northern California weed harvester whose simple operation explodes into comedic chaos after his big boss gets knocked off by the mob. Chong, sans Cheech, wrote, directed, and starred in this trippy road romp.
Keywords: ["Stoner","high","movie"]
Source: https://www.elitedaily.com/envision/stoner-flicks-21-greatest-90s-movies-inspired-weed/1390724
Who is Joe Rogan? Comedian revealed after Elon Musk smokes weed on his podcast show
Elon Musk created quite a stir when he appeared on comedian Joe Rogan's podcast Thursday night, smoking weed and sipping whiskey. Joe and Elon also shared some whiskey before the controversial tech genius launched into a tirade about a past meeting he took with President Obama. Joe has been criticized for having Elon on the podcast and the behaviour the two exhibited during their chat. Elon recently falsely claimed he was privatizing Tesla in a deal with Saudi Arabia and doubled down on calling a Thai rescue diver a pedophile. 'Black kids are still being arrested for smoking weed in many of America's cities, but Elon Musk and Joe Rogan are sitting here smoking blunts on camera in California. Another said: 'By ignoring every Elon Musk controversy, Joe Rogan is implicitly saying they don't matter.
Elon Musk appeared on the Joe Rogan Experience podcast on Thursday. During the interview, Elon smoked marijuana and drank whiskey while talking about Tesla, his other projects, personal and business connections and his childhood. For much of the interview, Elon appeared to be rambling. The company has lost a quarter of its value since August 7, the same day Elon tweeted that he'd arranged funding to privatize Tesla. Elon and Joe also discussed the threat of artificial intelligence.
Elon Musk's net worth is reportedly about $19billion.
Keywords: ["Elon","Joe","Tesla"]
Source: https://www.dailymail.co.uk/tvshowbiz/article-6143949/Who-Joe-Rogan-Comedian-revealed-Elon-Musk-smokes-weed-podcast-show.html
Here Are The 11 Stages People Who Can't Handle Weed Go Through When They Get High
I've tried, many times, and every time, I end up regretting it with every part of my soul. If you're like me, you might be able to relate to the stages I've gone every time I've ever been high. LIL DICKY – TOO HIGH / YOUTUBE. They're having the time of their life, in fact. CYRIAK / YOUTUBE.
But I realize I'm way higher than I originally thought. UGLY BETTY / ABC. Yeah, it's just weed, but I see and hear things that aren't there when I'm high. Stage 4: Someone tries to talk to me and it goes terribly. MODERN FAMILY / ABC.
Please go away stoned feeling. Stage 6: Mid freakout, my friends realize I'm not okay. MAD MEN / AMC. Anxiety is at an all time high and I can't even remember what I was thinking about two minutes ago. Stage 7: Now I believe all conspiracies I've ever heard.
Parks And Recreation / NBC. Life hack: curling up can protect you from bears and bad highs. I can feel my senses returning to me and the fear and anxiety are washed away and I feel like I'm finally crawling out of the pit of despair.
Keywords: ["high","feel","Stage"]
Source: https://wearemitu.com/comedy/confession-i-cant-smoke-weed-without-it-turning-me-into-a-horrible-pile-of-anxiety/
Marijuana-logues – 06.If Pot Could Talk
Tesla shares reel as executives quit and CEO smokes pot on webcast
Reuters) – Tesla Inc Chief Executive Elon Musk was filmed smoking marijuana and wielding a sword on a webcast, just hours before the automaker said its recently-appointed accounting chief would leave, the latest in a string of unusual behaviour and executive departures that have stunned investors. Shares of the electric carmaker tumbled more than 6 percent on Friday to $263.24, with investors on edge after a tumultuous August during which Musk proposed and then abruptly pulled the plug on a go-private deal. Chief Accounting Officer Dave Morton resigned after just one month in the job because of discomfort with the attention on the company and pace of work during that time, Tesla said in a filing on Friday. Later on Friday, Tesla named a new president of automotive operations, promoting eight-year Tesla employee and former Daimler truck exec Jerome Guillen into the role overseeing all automotive operations and reporting to Musk.That move, described in a company blog with several other promotions as a result of board and management discussions, gives Musk a seasoned auto industry veteran to lean on at a time when some investors have called for a new chief operating officer. Shares barely moved after hours, when the promotions were announced.
Morton and Toledano, whose departures come shortly after the U.S. Securities and Exchange Commission opened an inquiry into Musk's aborted privatisation plan, join dozens of senior executives who have left Tesla. Late on Thursday, Musk was filmed drinking whiskey, briefly smoking marijuana and wielding a Samurai sword during a 2-1/2-hour live Web show with comedian Joe Rogan that swiftly spread across social media. Analysts on Friday reiterated their call for Tesla to bring in another senior leader. SOBERING EFFECT ON INVESTORS.Tesla's $1.8 billion junk bond maturing in August 2025 plunged as much as 4 cents on the dollar to below 82 cents, a record low, in Friday trading, pushing the yield above 8.8 percent.
Coupled with an upfront cost of 21 percent of insured value, it now costs an investor around $280,000 to insure $1 million of Tesla debt for a year. With Tesla's stock falling to its lowest level since April, short sellers added 810,000 shares to their positions, bringing the total as of Thursday to about 32.6 million shares, according to S3 Partners, a financial technology and analytics firm. Tesla has told investors it expects to turn a profit in the second half of this year, a forecast the company's head of investor relations, Martin Viecha, reiterated at a conference earlier this week sponsored by RBC Capital Markets, RBC analyst Joseph Spak wrote in a note on Thursday.
Keywords: ["Tesla","Musk","investor"]
Source: https://www.yahoo.com/news/teslas-musk-smokes-marijuana-comedy-podcast-112350685–finance.html
7 Comedians Who Enjoy Marijuana
Although weed can definitely highlight what's weird about your surrounding or amplify already-comedic situations, it can't instill a fully-developed sense of humor. Doug Benson's comedy career revolves almost entirely around his love of cannabis. Benson created the 2008 documentary Super High Me, a druggy take on Morgan Spurlock's McDonald's exposé Super Size Me, in which Benson smokes weed in huge quantities every day for a month. Like a trippy version of Mike Nichols and Elaine May, collaborators Kate Berlant and John Early showcase a weird brand of character-based comedy in seemingly improvised skits like Family Dinner and Reunion. Berlant and Early's deadpan comedy is deeply rooted in the same pseudo-intellectual and fame-obsessed millennial culture that it satirizes, making for an especially meta comedy experience.
Each of the two wrote and starred in full episodes of the 2016 Netflix original comedy The Characters – Early's episode totally nails some cringe-worthy identities like a self-absorbed yuppie party host and a sassy but depressed Christian comedienne. Dave Chappelle staked a claim to stoner fandom early on in his career, having written, produced, and starred in the 1998 cannabis classic Half Baked. Chappelle briefly bowed out of the spotlight after Chappelle's Show was canceled in 2006 and now lives a low-key life with his family in suburban Ohio. A recent GQ interview with Chappelle yields some other great nuggets: he may have bought weed from Idris Elba back in the day, and once requested permission to smoke weed onstage from crack-smoking Toronto mayor Rob Ford. Jason Segel doesn't just play a cannabis enthusiast on TV.
He's well known for his love of weed, and has made a name for himself as a leading man in comedies like Forgetting Sarah Marshall and Jeff, Who Lives At Home, blending bumbling antics with undeniable sincerity. George Carlin is one of the first and arguably best full-fledged observational comedians. Carlin's countercultural humor was at least partially fueled by cannabis: in a retrospective interview with Jon Stewart, he claimed to.
Keywords: ["comedy","weed","smoke"]
Source: https://www.wikileaf.com/thestash/7-comedians-who-enjoy-marijuana/
Rick and Morty's Cannabis Subculture Warps Into Los Angeles
Trip out and chill in the Meatwad 4D Dome, or dive into a virtual-reality experience inspired by Dream Corp LLC, the Adult Swim show set in a sketchy dream-therapy facility. At 9 p.m. on Sunday, October 7th, Rick and Morty get a live showcase as composer Ryan Elder leads a 37-piece orchestra through musical highlights from the show in a Musical Ricksperience. As we prepare to run around at the Adult Swim Festival, we asked ourselves: why is there such a solid Rick and Morty. Just as cannabis helps connect us to the present moment, and enjoy things as they unfold, Rick and Morty deems friends, family, and doing what we love much more important than unanswerable questions about why we're here in the first place.
Take the McDonald's Szechuan sauce debacle, for instance. Twitter had a meltdown, and everyone had a good time making fun of Rick and Morty. Fan art is one of the most wonderful interpretative things in the world, and the weed-loving creatives who watch Rick and Morty have left no artistic pickle unjarred. To the fan art pot-culture pantheon with his collection of joints in the shape of Rick, Morty, and iconic characters Mr. Meeseeks and Mr.
Poopybutthole. To pairing a different strain of cannabis with each episode of the show. If you think your love of a TV show makes you better or smarter than other people, you should smoke a joint, and think about how you're missing the point. Tickets to the Adult Swim Festival Oct. 5-7 are available here. The festival does not permit medical or recreational cannabis onsite.
Keywords: ["Rick","Morty","show"]
Source: https://www.leafly.com/news/lifestyle/rick-and-morty-weed-subculture-warps-los-angeles
Legalize Marijuana 420 – Keith Lowell Jensen Stand-Up Comedy
High times: why TV is getting blazed on cannabis comedies
For years, marijuana was portrayed as either an evil gateway drug or as a prop to signify that the character using it was a hopeless, lazy slacker. While drug use on TV is not regulated by FCC rules, there are certain moral guidelines that networks were obliged to uphold, at least before 10pm. When the counter culture movement was thoroughly under way, the small screen dealt with it in one of three ways: ignoring it altogether, actively preaching against it or portraying it slyly, as exemplified by Scooby Doo's perma-stoned heroes, Shaggy and Scooby, who made their TV debut long before Cheech and Chong showed up in the 70s. By the 1980s Miami Vice was tackling drugs and Nancy Reagan was making a bizarre cameo in Diff'rent Strokes to promote the Just Say No campaign. For a long time any show that wanted to be positive about the issue had to side-step it, like That 70s Show, where the characters got stoned without a single spliff being seen on screen.
As attitudes towards weed soften and with it being decriminalized – if not quite legalized – in many more US states, the depiction of marijuana on TV is changing. Now we see characters using it in the same way that you'd previously show characters having a drink; it's a recreational activity that doesn't have any moralizing attached to it. Characters in Girls, Broad City, Mr Robot and more smoke, without it leading to a worthy storyline about addiction or a descent into crime. HBO has set the bar high by turning web series High Maintenance into a hit show this month. Each episode tells a different story, featuring different characters, all linked by the unnamed man who delivers their weed.
The characters all smoke, but that's not the main focus. The show is brilliantly unexpected – the first episode provides a wonderful subversion of the friendship between a gay man and a straight woman – but the weed is simply a device to explore these disparate characters. Netflix has also gotten in on the trend, ordering 20 episodes of Chuck Lorre's Disjointed, a comedy starring Kathy Bates as the owner of an LA-based cannabis dispensary, and Kevin Smith, a man who knows a thing or two about writing stoner characters, has filmed a spec pilot about a weed dispensary in LA. Even NBC has been considering a weed show, with Parks and Recreation star Adam Scott's Buds, a comedy set in a marijuana shop in Denver. Not all drugs are getting the comedy treatment – heroin and meth are still the reserve of heavy-going dramas – but TV producers have clearly loosened up when it comes to cannabis.
Keywords: ["character","drug","show"]
Source: https://www.theguardian.com/tv-and-radio/2016/sep/30/high-maintenance-hbo-cannabis-tv-comedies
Elon Musk smokes weed, sips whiskey on a comedy show
Elon Musk sipped whiskey and smoked marijuana during a 2 1/2-hour podcast with California comedian Joe Rogan that touched upon everything from flame throwers and artificial intelligence to the end of the universe. Musk, 47, took one drag from what Rogan described as a joint containing tobacco mixed with marijuana, which is legal in California. A Tesla spokesperson in Germany wasn't immediately available to comment. The spot on one of the most popular podcasts in the US marks Musk's first appearance in a public forum since he stunned the financial world last month with his short-lived effort to take Tesla private. Along the way, Musk drew a subpoena from the Securities and Exchange Commission, which already had been scrutinizing the public pronouncements he's made regarding manufacturing goals and sales targets.
Tesla and its CEO are now also facing a litany of lawsuits claiming market manipulation, including one filed Thursday by Andrew Left, the founder of Citron Research and prominent short seller. The episode also raised concern about Musk's health. The bewildering incidents have played out during a critical period for Tesla. The Palo Alto, California-based company faces concerns about its limited cash balance, maturing debt and struggle to steadily build high volumes of the Model 3 sedan, the first electric vehicle that Musk has attempted to mass-manufacture. Musk told Rogan that running Tesla is the hardest of his several endeavors.
Musk is also the founder of the tunneling startup Boring Co., plus Neuralink, which is developing brain-machine interfaces to connect humans and computers. Neuralink may have something interesting to announce in a few months, Musk told Rogan.
Keywords: ["Musk","Tesla","Rogan"]
Source: https://www.hindustantimes.com/business-news/elon-musk-smokes-weed-sips-whiskey-on-a-comedy-show/story-PFKAaW15XOGHE6rasfVZgP.html
Comedy sketch imagines a sobriety test for stoners / Boing Boing
CBC Comedy sketch comedy series 22 Minutes humorously imagines what a pot sobriety test might look like, cookie dough and all. People make art because they have to, and there's always a middle-man ready to take advantage of the oversupply of willing creators to grab our rights and pay us peanuts. No matter how diligent we are about managing them, there's always a mountain of clutter waiting for us when we start our day. That's why demand is high for experts who can keep these businesses online. Now, demand alone won't get your foot in the door, as employers expect you to bring some certifications to the table that validate your skills.
Keywords: ["demand","there's","Comedy"]
Source: https://boingboing.net/2018/08/18/comedy-sketch-imagines-a-sobri.html
US border control has some weird new weed policies… | 22 Minutes
Elon Musk to resign as board chairman of Tesla, pay $20 million fine
That's a high price to pay for a stupid pot joke. Elon Musk must step down as chairman of the board of Tesla for three years – and he and the car company will each forfeit $20 million – under a punishing settlement forced by the Securities and Exchange Commission. When first questioned by the SEC, Musk confessed that he had settled on the $420 figure to make a dumb pot joke to impress his girlfriend. Musk will remain chief executive of Tesla, the SEC said in announcing the settlement Saturday. In accepting the settlement terms, Musk has neither admitted nor denied the SEC's civil allegations that he committed fraud by misleading his investors.
The settlement terms are slightly tougher than those Musk had rejected during negotiations Thursday, The New York Times reported, citing two people briefed on the talks. Those earlier terms would have barred him from serving as chairman for two years instead of three and would have cost him a $10 million fine instead of $20 million. The SEC made an initial hardball offer before filing Thursday's lawsuit, under which Musk would have stepped down for two years as both chair and CEO, effectively severing all ties to Tesla. The SEC slap comes two months after Musk earned the feds' ire with a Wall Street-blindsiding Aug. 7 tweet teasing that he planned to take the company private. Tesla's own executives had been caught unawares.
He had calculated a potential share price of $419 by taking that day's closing share price and tacking on a 20 percent premium, the feds alleged in the lawsuit. Earlier this month, Tesla fell to its lowest point in five months after he smoked marijuana on a Joe Rogan podcast.
Keywords: ["Musk","Tesla","SEC"]
Source: https://nypost.com/2018/09/29/elon-musk-to-resign-as-board-chairman-of-tesla-pay-20-million-fine/
Elon Musk smokes marijuana live on web show
YOUTUBE/POWERFULJRE Tech entrepreneur Elon Musk has smoked marijuana live on the web during a podcast with comedian Joe Rogan. Mr Rogan offered his guest the drug, which is legal in California, as the pair discussed tech innovation and the public's perception of Mr Musk. Tesla shares fell more than nine per cent following Mr Musk's appearance on the show. BBC business correspondent Kim Gittleson says the podcast appearance coupled with the departure of a key executive who blamed increasing public scrutiny of the company for his decision to leave has shaken investor confidence in Tesla. His controversial plans regarding Tesla's ownership were dropped about two weeks later, following outrage from some investors.
From his frequent tweet storms, to accusing a British rescue diver in Thailand of pedophilia, to a quick u-turn on an effort to take Tesla private – it's no wonder both investors and his closest friends have begun to worry. When it comes to Tesla, the erratic behaviour of Mr Musk might be the least of the company's problems. Tesla has long been one of the most bet-against stocks on Wall Street. While that's something that has long frustrated Mr Musk, this certainly won't change that. During the podcast, Mr Rogan offered Mr Musk a joint, which he said contained a mix of tobacco and marijuana – dried leaves and flowering parts of the female cannabis plant.
During their conversation, Mr Musk talked about his health and his management of Tesla – which he said was the most challenging of his various businesses and projects. To close the podcast, Mr Musk was asked if he had any concluding remarks.
Keywords: ["Musk","Tesla","podcast"]
Source: https://www.bbc.com/news/technology-45445554
What is the NW Cannabis Club in Portland Oregon?
A unique venue, where you can enjoy international independent films, as well as, legally use Marijuana or Cannabis products in Portland, Oregon. NW Cannabis Club isn't only a legal Marijuana Theater in Portland Oregon. It is a members only club that allows Marijuana smoking, vaping, edibles and dabbing while watching movies on a giant screen. There is also plenty of indoor social areas with pool tables, video games, board games, chess, couches, lounge areas and an alcohol-free bar with low priced munchies. You can't actually purchase Marijuana or Cannabis products inside the club, but you can bring your own bud and consume it legally.
You must be 21 Years Old to enter or become a member of the NW Cannabis Club. Film Festival Circuit Inc. has partnered with the NW Cannabis Club to show independent international films on special event nights. The Northwest Cannabis Club is not a pure theater, it offers so many entertainment options for it's members. There are painting classes, live stand-up comedy, live musical guests, Cannabis auctions, Celebrity Dab Wars and now Film Festivals as well.
There is a one-time charge of $20 cash at the door to become a member of this private club. On Horror Film Thursdays and the Portland Comedy Film Festival, each day offers 4 hours of films. You must be 21 Years Old to enter or become a member of the NW Cannabis Club..
Keywords: ["Film","Cannabis","Club"]
Source: http://filmfestivalcircuit.com/sponsors/nw-cannabis-club/
Elon Musk smokes marijuana on Joe Rogan's podcast
Tesla's Elon Musk provoked another Twitter storm on Friday by briefly smoking marijuana on a live web show with comedian Joe Rogan. The forty-seven year old billionaire spent two and a half hours on a podcast late Thursday discussing everything from artificial intelligence and its impact on humankind to flame throwers and social media. Musk stunned investors a month back with tweets saying he had funding to take the company private for $420 per share. He then backed off from his plan saying Tesla was better off as a public company. He followed it up with fresh attacks on British cave diver Vernon Unsworth.
Neither Tesla nor Musk have commented on the Buzzfeed report. Musk apologized to Unsworth in July for similar insults he made on Twitter following the rescue of a dozen Thai schoolboys and their football coach from a cave in Thailand. The billionaire's behaviour has raised concerns about his leadership and several Wall Street analysts have called for the company to appoint a strong No. 2 to prop up Tesla's operations and standing with investors. His followers on Twitter went into a frenzy following the podcast. Several followers questioned if it was against the company's policy, while others mocked the CEO's initial $420 bid, a number that has become code for marijuana.
Keywords: ["Musk","Tesla","followed"]
Source: https://globalnews.ca/news/4433183/elon-musk-marijuana-joe-rogan-comedy-podcast/


Not them. All had one fin and were flown from ahead of it.
… so here's a question to be going on with. What aircraft was flown from between its tail fins?
After a month … bump?
Unfortunately I couldn't find any info regarding the faith of the Mike Banyard's Seafire after 'Operation Iceberg'.
Had to land on US carrier after its own was danaged?
The first part is correct, the second isn't.
Yepp. Now how was it acquired?
I'm guessing a Corsair after it's home carrier, Formidable, was damaged?
During 'Operation Iceberg' (the Okinawa campaign), the USN (unexpectedly) acquired a RN FAA airplane belonging to the British Pacific Fleet. What type was it and how was it acquired?
What U.S.N. carrier(s) first operated the F4U in combat as part of their regularly assigned air group?
Boom. Another one for RR! Back to you, my friend!
VF-17 was the first to operate the Corsair off the Bunker Hill in July 43, stateside. They were pulled off it though and sent to the Solomons in a land-based role. Main issue was ensuring they had supplies and parts which wouldn't really be available through the USN chain being the only Corsair unit at the time on a carrier so they teamed them up with the USMC units.
During that assignment though they did land back on the Bunker Hill on occasion to refuel and rearm during attacks on Rubal.
Nope, that's not it. While VF-17 was originally assigned to the Bunker Hill air group, they didn't accompany the ship into the combat zone. They did indeed land during Rabaul operations, but really only as a pit stop, not as a regular thing.
The unit I'm looking for actually operated as a regular part of the air group of the carrier(s) in question.
Oops, now I've gotta come up with a question. Rats.
OK. No doubt an easy one, but here goes.
The F4U Corsair was at first considered unsuitable for carrier ops by the US Navy for several technical reasons, so it was sent to the Marines (who made damn good use of it!) But it was used on American flattops earlier that usually thought. What U.S.N. carrier(s) first operated the F4U in combat as part of their regularly assigned air group, which squadron flew them, and what was their mission?
All right, here we go again: Col. Iftach Spector, an IAF ace with 12 aerial victories, was one of the 8 F-16 pilots who participated in operation 'Opera', Israel's bombing of Iraq's nuclear reactor in June '81. As far as the results of this daring raid go, what set him apart from the rest of the pilots?
I believe he's the only one who didn't hit the target. Did I?
Michael, before I've posted this question I knew already you'll give the right answer...after all, you don't have his photo as your avatar for nothing, do you?
The tail reminds me of various Bell aircraft. Is it a Bell of some description?
Not a Bell, but you've nailed the nationality in one shot.
The Canberra, depending on sources it was either planned to operate them in Chilean markings or the actually did operate in Chilean markings. There are supposedly photos of Canberras in Chili during the Falklands War.


text:
Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control – Continuous Glucose Monitoring is the Solution
Published Online: August 24th 2018 European Endocrinology, 2018;14(2):50–6 DOI: https://doi.org/10.17925/EE.2018.14.2.50
Authors: Peter Adolfsson, Donald Rentoul, Brigitte Klinkenbijl, Christopher G Parkin
We queried PubMed and other internet databases to identify studies, meta-analyses, review articles and other data sources regarding hypoglycaemia incidence/costs/impacts and continuous glucose monitoring (CGM) use. Our analysis of the evidence showed that hypoglycaemia remains a significant health concern and a primary obstacle to optimal adherence to prescribed diabetes treatment. In addition to its adverse clinical consequences, hypoglycaemia negatively impacts quality of life and places additional financial burdens on patients, patient families, employers and healthcare payers. Clinical trials have shown that the use of CGM can reduce the incidence and duration of hypoglycaemic episodes. This article reviews relevant CGM studies, discusses the prevalence and clinical/financial implications of hypoglycaemia, and explores the strengths and limitations of current CGM systems in minimising the burden of hypoglycaemia.
hypoglycaemia, nocturnal hypoglycaemia,
impaired hypoglycaemia awareness,
continuous glucose monitoring, quality of life
Intensive insulin therapy is recommended for the management of type 1 diabetes (T1D),1 and has been shown to be an effective and beneficial treatment modality for many individuals with type 2 diabetes (T2D).2,3 During the past decade, we have seen several new insulin preparations and delivery devices that enable individuals with diabetes to achieve near-normal glycaemia. However, despite advances in insulin therapy and ways to deliver insulin, a large proportion of individuals with insulin-treated diabetes are still not achieving their treatment goals.4,5
Suboptimal treatment adherence is often identified as the underlying cause of poor diabetes control. However, adherence is often driven by several factors over which patients have little control, such as cost, complexity of dosing regimens, patient-provider interaction and others.6 Moreover, anecdotal evidence suggests that many patients with diabetes do not know how to identify and interpret their glucose monitoring results or how their medications and health behaviours actually influence their glucose levels.7,8
Although these factors clearly play a major role in suboptimal treatment adherence, hypoglycaemia remains a key obstacle to achieving desired glycaemic control in insulin-treated diabetes.9 Numerous studies have shown that many individuals with insulin-treated diabetes are unable to meet their glycaemic targets without excessive and/or severe hypoglycaemia.9–11
Recent advances in continuous glucose monitoring (CGM) technologies may now empower individuals with insulin-treated diabetes to minimise or avoid severe hypoglycaemia as they achieve desired glycaemic control. In this article, we review the adverse clinical and financial consequences of severe hypoglycaemia and discuss current options for the use of CGM, real-time CGM (rtCGM) and intermittent scanning CGM (isCGM) – by individuals with insulin-treated diabetes to safely manage their diabetes.
What do we know?
Several recent studies have demonstrated the clinical utility of CGM in reducing hypoglycaemia in T1D12–17 and multiple daily insulins injection-treated T2D.18,19 Because most of these studies have been reviewed in the literature, further comment on them is not needed. However, findings from the HypoDE,16 GOLD-317 and IMPACT (subgroup analysis)20 studies are relevant to our discussion and provide important insights into the value of CGM specific to hypoglycaemia reduction and prevention.
In the HypoDE study, which included patients with MDI-treated T1D with problematic hypoglycaemia (severe hypoglycaemia and/or impaired hypoglycaemia awareness), investigators found that the number of hypoglycaemic events can be markedly reduced by the use of rtCGM compared with reliance on conventional blood glucose monitoring.16 Investigators also reported that rtCGM use resulted in a significant decrease in the frequency of clinical severe hypoglycaemia and reduced glycaemic variability, a known risk factor for hypoglycaemia.21,22
The GOLD-3 study looked at the effects of rtCGM within a cohort of patients with MDI-treated T1D with varying degrees of hypoglycaemia.17 Study outcomes included time in nocturnal hypoglycaemia (<70 mg/dL [<3.9 mmol/L] and <54 mg/dL [<3.0 mmol/L]), number of nocturnal and daytime hypoglycaemic events, and daytime hypoglycaemia and hypoglycaemia confidence, as measured by the Hypoglycaemia Confidence Scale.23 Investigators observed significant reductions in nocturnal and daytime hypoglycaemia among rtCGM users compared with blood glucose monitoring. For participants randomised to start with rtCGM, the time in hypoglycaemia decreased during rtCGM use but increased when rtCGM use was stopped prior to the washout period. In addition, rtCGM users reported increased confidence in their ability to detect and respond to impending hypoglycaemia. This finding has positive clinical implications, given the relationship between the fear of hypoglycaemia and adherence to suboptimal medication.24,25
The IMPACT study assessed the impact of FreeStyle Libre isCGM system (Abbott, Chicago, IL, US) use on hypoglycaemia compared with capillary glucose monitoring in individuals with well-controlled (glycated haemoglobin [HbA1c] ≤ 7.5% [58 mmol/mol]) T1D treated with MDI therapy – individuals with impaired hypoglycaemia awareness were excluded.13 Participants in the intervention group used FreeStyle Libre throughout the study and could obtain flash glucose readings during the final 14-day period and adjust their blood glucose control accordingly, whereas the control group used self-monitoring of blood glucose (SMBG) and wore a blinded FreeStyle Libre during the final 14-day period. A pre-specified subgroup analysis showed that the use of the FreeStyle Libre system significantly reduced time in hypoglycaemia without deterioration of HbA1c, and improved treatment satisfaction, with the proviso that the individuals scanned their device frequently (average of 15 times a day).20 The significance of these findings were questioned by Warren,26 noting that 'it would be extremely surprising if individuals who could see their flash glucose levels did not keep them in target more effectively than blinded individuals'. It is our view that the results reported in the IMPACT study simply show that FreeStyle Libre is a better option than SMBG but requires frequent scanning to reduce hypoglycaemia. Recently, the authors of the IMPACT trial responded that the methodology was indeed noted in the original article, but that there was no other practical alternative to this approach.27
However, the degree of hypoglycaemia reduction achieved varies between CGM systems. The recent IHART trial, a head-to-head comparative study, demonstrated that the use of the Dexcom G5 system more effectively reduces the time spent in hypoglycaemia than with FreeStyle Libre use in MDI-treated T1D adults with impaired hypoglycaemia awareness.28
Why do we care?
Hypoglycaemia is prevalent
The latest estimates of the frequency of hypoglycaemia range from 42–91 events per patient-year for T1D adults and from 20.3–44.4 events per patient-year for T2D adults.29 Data from the T1D Exchange registry indicate that approximately 11.8% of adults and 6.2% of children/adolescents experience at least one episode of severe hypoglycaemia per year.30,31 In a 2005 survey by Akram et al., 16.5% of 401 patients reported at least one severe hypoglycaemic event within the past year.32 In contrast, lower frequency of severe hypoglycaemia has been reported in Sweden where 60% of children used an insulin pump, 80% used a CGM device and only 2.1% had a severe hypoglycaemia event during 2016.33
Key contributors to severe hypoglycaemia are asymptomatic hypoglycaemia (impaired hypoglycaemia awareness) and nocturnal hypoglycaemia.34 Both conditions impede patients' perception of hypoglycaemia when it is occurring and, thus, limits their ability to take appropriate action. Impaired hypoglycaemia awareness results from frequent hypoglycaemic events (severe and non-severe).35 Nocturnal hypoglycaemia accounts for a significant proportion of hypoglycaemic events and often goes undetected.36 In an early study of 70 patients using CGM, data revealed unrecognised hypoglycaemia in 62.5% patients with T1D and 46.6% of patients with T2D – 73.7% of all episodes occurred during the night.37 Nocturnal hypoglycaemia is particularly concerning among adults and children after physical exercise.38,39 As reported by Gomez et al., the risk of hypoglycaemia is elevated for at least 24 hours in recovery from exercise, with the greatest risk of nocturnal hypoglycaemia occurring after afternoon activity.38
Among adults with T1D, severe hypoglycaemia is more related to long duration of diabetes and socioeconomic status than HbA1c,30 whereas factors such as being non-white, no health insurance and lower household income were associated with higher frequency of severe hypoglycaemia among T1D children/adolescents.31 Conversely, severe hypoglycaemia is most common in T2D adults (treated with insulin or secretagogues) with impaired hypoglycaemia awareness.32
Severe hypoglycaemia is particularly concerning among elderly patients with diabetes. These patients are at significantly higher risk due to their age, diabetes duration, insulin therapy duration, glucose variability and higher prevalence of impaired hypoglycaemia awarewness.10,11,40–42 Cognitive and physical impairments and other co-morbidities further increase the risk of severe hypoglycaemia among older patients.42
Although targeting lower HbA1c has been cited as a key contributor to severe hypoglycaemia, an analysis of the T1D Exchange data showed that this condition is common in adults with T1D with both higher and lower HbA1c levels.30 Moreover, national data from Sweden show that it is possible to improve both HbA1c and reduce severe hypoglycaemia with insulin pump and CGM use – however, the technology has to be used properly.33 Severe hypoglycaemia is also common among older adults with T2D across all levels of glycaemic control. The risk tends to be higher in patients with either near-normal glycaemia or very poor glycaemic control.43
New cut-points for hypoglycaemia
Cut-points and definitions of hypoglycaemia have been debated over the years. However, an international panel of clinicians and researchers with expertise in CGM technologies recently published consensus recommendations for classifying and defining hypoglycaemia from data derived from CGM use.44 The panel described three levels of hypoglycaemia (Table 1) and recommended that hypoglycaemia should be quantified in the following ways: percentage of time spent in the hypoglycaemic ranges (<70–54 mg/dL [<3.9–3.0 mmol/L] or <54 mg/dL [<3.0 mmol/L]), the number of minutes or hours below these levels, and the number of hypoglycaemic events that occur over the given CGM reporting period.44 An event was defined as any episode of hypoglycaemia that lasts ≥15 minutes. Glucose levels ≥70 mg/dL (3.9 mmol/L) ≥15 minutes indicate that the event has ended.
Hypoglycaemia impacts lives
Clinical consequences
The clinical consequences of severe hypoglycaemia are well known and include: precipitation of acute cerebrovascular disease; myocardial infarction; neurocognitive dysfunction; and loss of vision.44 Left untreated, severe hypoglycaemia can result in significant morbidity and mortality.46,47
As discussed earlier, nocturnal hypoglycaemia is a significant risk factor for severe hypoglycaemia and is thought to be linked to sudden death during sleep.48 Although asymptomatic, nocturnal hypoglycaemia can trigger sleep disturbances in patients, resulting in morning headache, chronic fatigue and/or mood changes.45
Severe hypoglycaemia is extremely problematic in paediatric patients, often resulting in convulsions or enuresis during nocturnal hypoglycaemic episodes.49 It is also linked to long-term cognitive impairment in paediatric patients with T1D. A 16-year follow-up study found that T1D children who experienced severe hypoglycaemia at an early age (≤10 years) had poorer cognitive function in adulthood, and that deficits were found across several cognitive domains, particularly among patients exposed to severe hypoglycaemia before the age of 6 years.50 Some studies have reported decrements in the domains of intelligence quotient (IQ), executive functions, delayed memory and processing speed in childhood-onset T1D. However, these decrements are often not observed until the children are studied later in childhood.51 It has been suggested that 'chronic exposure to different aspects of dysglycemia is additive, and that brain and cognitive changes only become apparent over time'.51
Hypoglycaemia fear
The frequency of severe hypoglycaemic episodes is a central driver of hypoglycaemia fear,9,52–54 which can result in suboptimal insulin treatment adherence and adverse health outcomes.24,25 Patients who are fearful of hypoglycaemia are often reluctant to adhere to their prescribed insulin regimens,9,55 leaving them at high risk for developing the microvascular and macrovascular complications of hyperglycaemia.1,56–58 A recent international survey of 27,585 patients with diabetes found that reducing insulin doses in response to hypoglycaemia was common, ranging from 33.6–51.7% in patients with T1D and from 25.8–46.7% in patients with T2D.29 Moreover, parental fears can prompt 'hypoglycaemia avoidance' behaviours, which lead to poor glycaemic control and increased risk of long-term complications.25,59
The direct costs of treating severe hypoglycaemia (emergency department care and/or hospitalisations) vary from country to country. Relatively recent data from Germany, Spain and the UK estimate the average costs per event to be €441, €577 and €236, respectively, for patients with T1D, and €533, €691 and €537, respectively, for patients with T2D.60 Costs are much higher in the USA, with an average cost of $1,387 per event.61
However, all levels of hypoglycaemia (non-severe, significant, severe) also confer significant indirect costs on employers as well as individuals with diabetes.62,63 A recent study showed a clear link between severe hypoglycaemia and the costs of lost productivity.62 According to the report, mean annualised indirect costs due to lost productivity rose with increasing severity of hypoglycaemia: $7,248, $7,493 and $12,167, respectively.62 The adverse economic impact on patients due to increased out-of-pocket expenses, decreased productivity and lost workdays is equally notable, with the highest loss in productivity attributable to non-severe nocturnal hypoglycaemic events.63
Although the economic consequences of hypoglycaemia are, indeed, significant, they are overshadowed by its adverse effects on patients' lives. Numerous studies have shown that hypoglycaemia negatively impacts patients' ability to concentrate and participate in daily activities,64 thereby negatively impacting patients' quality of life.65 Patients who experience frequent episodes of hypoglycaemia often feel powerless, creating anxiety for themselves and their families, and mood swings, irritability and feelings of depression are common.66,67 A key contributor to diminished quality of life is chronic sleep interruption caused by nocturnal hypoglycaemia, itself, and fear of hypoglycaemia.68,69 A recent survey by Barnard et al. found that chronic sleep disruption is common among patients and parents/caregivers, and is associated with detrimental impacts on virtually all aspects of daily life.68
Even non-severe hypoglycaemia, which occurs in 24–60% of patients with diabetes, can adversely affect quality of life. The greatest reductions in quality of life are seen among those participants reporting a higher frequency of non-severe hypoglycaemia.65 As reported by Geelhoed-Duijvestijn et al., it takes an average of 50.4 minutes to return to normal functioning following a daytime non-severe hypoglycaemic event, but negative feelings persisted for an average of 5.4 hours.70 Following a nocturnal non-severe hypoglycaemic event, functionality was diminished for an average of 80.5 minutes and negative feelings persisted for 12.2 hours.70
Hypoglycaemia at all levels places an additional layer of stress and frustration on individuals with diabetes who are already burdened with the complexities of daily diabetes management. It is, therefore, gratifying that recent studies have shown that isCGM, as well as rtCGM, use improves glycaemic outcomes and quality of life in patients with T1D12–17,20 and patients with T2D treated with intensive insulin therapy18,19 regardless of hypoglycaemia incidence and severity. However, it is important that patients and their clinicians understand the strengths and limitations of various CGM systems in order to select the most appropriate system that meets their individual needs.
Which CGM features are most important?
Patients who choose to use CGM have several options available to them, standalone devices or insulin pump systems with integrated CGM. Because some integrated pump systems (Medtronic 640G and 670G) address hypoglycaemia by automatically suspending or reducing insulin infusion, we have focused only on current systems, which can be used as standalone devices or other insulin pump systems (Table 2). There are distinct differences between systems in terms of accuracy, indications for insulin dosing, alarms and alerts, wear time, convenience features and cost.
We recently published suggestions for the appropriate selection of CGM devices based upon matching the various CGM systems to individual patients' needs for daily self-management.71 In this article, we narrow our focus to the specific system attributes that are most relevant to addressing hypoglycaemia: accuracy in the hypoglycaemic ranges, continuous automatic transmission of glucose data, active audible alarms, and data sharing (Table 3).
Accuracy in hypoglycaemic range
Accuracy in all glycaemic ranges is required for the safe and effective use of CGM. Although the overall accuracy (mean absolute relative difference) of the various devices is mostly similar (Table 3), accurate and reliable data in hypoglycaemic ranges is particularly critical. The obvious danger is that failure to detect hypoglycaemia will likely result in an acute (potentially severe) hypoglycaemic event. Conversely, an erroneous low-glucose reading may prompt users to correct with food, resulting in avoidable hyperglycaemia. Importantly, persistence in CGM use is impacted by patients' perceptions of the accuracy and reliability of their CGM devices.79
Inaccuracy in the lower-glucose ranges is a characteristic of all current CGM devices. As shown in Table 3, the overall accuracy of the Dexcom, Libre and Eversense systems is relatively similar, however lower overall accuracy has been observed with the Guardian 3. Differences in accuracy are also seen in the lower-glycaemic ranges. The accuracy of the Libre and Dexcom G6 in the lower ranges are comparable when measured by mean absolute difference, however comparison of matched CGM-reference pairs in the lowest range (≥40–60 mg/dL [≥2.2–3.3 mmol/L]) show much lower CGM-reference value concurrence with the FreeStyle Libre system. Abbott Diabetes Care addresses this issue by advising FreeStyle Libre users to perform a confirmatory finger-stick test when sensor values are in the low-glucose range.
Differences in study designs, methodologies, metrics and other factors make it difficult to draw direct comparisons between systems, however the substantial difference between the FreeStyle Libre and rtCGM systems (as demonstrated using standardised methodology) cannot be ignored. Concerns about inaccuracies of the FreeStyle Libre system were recently reported by Fokkert et al., who observed a low-glucose bias in the lower ranges and underestimation of postprandial glucose response.77
Although lower accuracy in the lower-glycaemic ranges is common in all systems, reduction or prevention of hypoglycaemia can be achieved by taking action before the level of hypoglycaemia is reached. Automatic audible alerts in the rtCGM devices provide additive protection when glucose values decrease rapidly.
Automatic data transmission
All current CGM systems continuously monitor glucose levels in interstitial fluid. However, an important difference between the FreeStyle Libre system and the other systems is how data are delivered to the user. With the Dexcom G6, Dexcom G5, Guardian 3 and Eversense systems, glucose data are transmitted automatically to the user's receiver and/or smartphone in real time.
Active alarms
Active audible alerts and alarms automatically warn rtCGM users when glucose levels rise or fall beyond a defined glycaemic threshold or when glucose values rapidly increase or decreases beyond a defined threshold (e.g., predictive alerts). Beyond this, trend arrows indicate both the direction and velocity of changing glucose, thus enabling users to take appropriate pre-emptive action to prevent impending glycaemic events. This around-the-clock vigilance is particularly important for patients with frequent severe hypoglycaemia, nocturnal hypoglycaemia and/or impaired hypoglycaemia awareness.
The Dexcom G5, Dexcom G6, Guardian 3 and Eversense systems feature programmable active audible alarms. The Dexcom G5 and G6 Mobile App feature allows users to schedule and customise a second group of alarms that only apply during the hours specified (e.g., work hours). The Guardian 3 system features customised predictive alarms – from 10 minutes up to 1 hour – allowing users additional time to respond as needed. The Eversense system provides on-body vibration alarms when an alert level has been reached and triggers the mobile device app to sound an alert and display messages on the screen.
The FreeStyle Libre does not offer automatic alarms. Instead, users must scan frequently to receive information about actual glucose value, an 8-hour glucose history and trend arrows. The individual must then rely on their ability to recognise impending and acute hypoglycaemia.
Real-time data sharing
The ability to share real-time glucose data with family members, friends and caregivers provides a potent safety net for all CGM users who are vulnerable to severe hypoglycaemia, such as adults who travel frequently and elderly patients who are at increased risk for severe hypoglycaemia due to impaired awareness10,11,40–42 and/or cognitive and physical impairments.42
The use of real-time data sharing is particularly valuable in paediatric patients because it allows parents to monitor their child's glycaemic status at school, during physical activity and throughout the night. This not only provides an added layer of safety for the child, but also supports better overall diabetes management by reducing hypoglycaemia fear among parents. Moreover, rtCGM offers the ability to achieve good nocturnal glucose control while receiving an alert/alarm in case the glucose value passes a predefined level. Therefore, parents/guardians can sleep well during most nights while being warned during the nights when needed. Thus, rtCGM even improves health in a more general way.
In a recent study, Erie et al. surveyed parents and daytime caregivers of 33 paediatric patients with T1D who used a CGM device (Dexcom or Medtronic) with real-time data sharing.80 Fifty-seven survey pairs were distributed, and 33 parent surveys and 17 daytime caregiver surveys were returned to the investigators. Results showed that all parents and 78% of caregivers felt that use of the data-sharing feature decreased their worry or stress. Table 4 presents some of the parent/caregiver open-ended responses reported in the study.
All current CGM systems offer data-sharing abilities but with distinct differences in functionality. The Dexcom G5/G6, Eversense and Guardian 3 systems allow sharing of real-time glucose levels and trends to up to five 'followers', whereas the FreeStyle Libre system allows sharing with up to 20 followers.
There are differences in the type of data that is transferred. The Dexcom G5 and G6 systems provide current glucose values, trend arrows and trend graphs. The Eversense system shares the current glucose value and trend arrow. With the Guardian 3 system, the follower receives a message and must then connect to the web browser + follower function (via the CareLink Connect service) to investigate the reason behind the alert. The FreeStyle LibreLinkUp app provides current glucose values and trend arrows, however it requires users to scan the sensor in order to send glucose data to followers. This significantly limits the follower's ability to detect and warn the patient of impending or acute severe hypoglycaemia when the patient is sleeping. The same kind of restriction applies to physical exercise which is a situation associated to both hyper- and hypoglycaemia. Although scanning is a quick and simple procedure, this product attribute does not allow the use of active alarms and continuous, automatic real-time data-sharing, which we feel are critically important features relative to hypoglycaemia detection/prevention and patient safety.
All of the current CGM systems provide significant advantages over traditional blood-glucose monitoring. A key strength of the Freestyle Libre or isCGM is that the system is easy to start with, intuitive to function and marketed at a relatively low price. Thus, it is a much more effective and easier way to measure glucose levels compared to SMBG. For patients without problematic hypoglycaemia, a number of factors (e.g., convenience, cost, ease-of-use) should of course be considered when selecting a CGM system. However, for patients who are at increased risk of severe hypoglycaemia, the attributes discussed here – accuracy in the low-glucose range, automatic data transmission, active alerts/alarms and real-time data sharing – should be priority considerations.
As shown in Table 2, accuracy in the lower-glucose ranges is an issue for all current systems, and some systems perform better than others. It is our view that active alarms 'trump' accuracy in prevention and detection for patients with frequent non-severe hypoglycaemia, frequent severe hypoglycaemia, nocturnal hypoglycaemia and/or impaired awareness. An early warning of impending hypoglycaemia provides the opportunity to take corrective action to prevent a severe event. The ability to share data with others in real time is another important safety feature that should be considered.
The Dexcom G5, Dexcom G6, Guardian 3 and Eversense systems offer these protections. Although frequent scanning with the FreeStyle Libre system provides some protection during the day, it cannot detect nocturnal hypoglycaemia when the user (or caregiver) is sleeping or warn the physically active individual about a pending hypoglycaemia. Therefore, it is our recommendation that the use of the FreeStyle Libre in patients with problematic hypoglycaemia should only be considered when cost or other factors prohibit the use of a real-time CGM system. However, when considering the cost of a specific device, it is important that both patients and healthcare payers factor in the known costs of hypoglycaemia as they relate to clinical risk and consequences, increased hospitalisations and emergency care, diminished productivity, additional financial burden on patients and poor quality of life. When viewed from this perspective, initial cost of a device is far outweighed by total cost if the device does not provide adequate protection against hypoglycaemia. In some European countries, the prescription of rtCGM is required for individuals with impaired awareness or other problematic hypoglycaemia, and they are not eligible for isCGM reimbursement.
Severe hypoglycaemia poses a significant health risk and is a costly complication for patients with MDI-treated diabetes. It is particularly dangerous in patients with impaired hypoglycaemic awareness and when it occurs during the night. The fear of severe hypoglycaemia and resulting hypoglycaemia are key drivers of suboptimal adherence to prescribed insulin therapy, which can lead to increased risk for long-term microvascular and macrovascular disease.
Although inaccuracy in the lower glucose ranges remains a limitation for all current CGM systems, devices that provide automatic 'predictive' alerts before glucose falls into the hypoglycaemic range mitigates this limitation. Automatic sharing of this predictive information with family members, friends and/or caregivers further reduces the risk of both moderate and severe hypoglycaemic events.
In addition to improvements in HbA1c and patients' quality of life, current CGM technologies enable patients to detect and prevent severe hypoglycaemia. However, given the different functionalities and varying levels of protection provided by current CGM systems, it is important that patients and their clinicians carefully consider the strengths, weaknesses and appropriateness of each system as they apply to individual needs.
Numerous recent studies have demonstrated the clinical efficacy and other benefits of CGM use in individuals with T1D and T2D regardless of the insulin delivery method used.12,14,18,81–85 Driven by advances in accuracy, functionality and usability, CGM adoption has increased dramatically over the past decade, and its use should be encouraged in all insulin-treated patients. As advances in CGM technology continue, we anticipate even greater accuracy and more convenience features in future CGM systems.
Moreover, we will see increasing adoption of data visualisation/interpretation tools such as the Ambulatory Glucose Profile (AGP), which automatically calculates a number of key metrics – time in glucose ranges (low, target, high), estimated HbA1c (eHbA1c) and glycemic variability. With AGP information, in combination with the individual day-profiles (which can include medication, carbohydrate-intake, exercise and other event details), healthcare professionals can more effectively collaborate with their patients as they review the data, discuss problematic issues and agree upon solutions that are individualised to the needs of each patient. Thus, CGM technologies may contribute greatly to minimising the important 'hypoglycaemia' side effect of intensive insulin therapy, and improve both outcomes and quality of life for people with diabetes.
Peter Adolfsson has received a
research grant from Novo Nordisk and consulting
fees associated with lectures/meetings from Eli Lilly,
Novo Nordisk, Abbott, Dexcom, Medtronic, Nordic
Infucare, Roche and Rubin Medical. Christopher Parkin
has received consulting fees from CeQur, Dexcom,
Insulet, Johnson & Johnson, Mannkind, and Roche
Diabetes Care and Senseonics. Donald Rentoul and
Brigitte Klinkenbijl are employees of Dexcom.
Double-blind review.
All named authors meet the International
Committee of Medical Journal Editors (ICMJE) criteria
for authorship of this manuscript, take responsibility
for the integrity of the work as a whole, and have
given final approval to the version to be published.
Christopher G Parkin,
CGParkin Communications, Inc., 2352 Martinique,
Henderson, NV 89044, USA. E: chris@cgparkin.org
Funding for the development of this manuscript
was provided by Dexcom, Inc., San Diego, California, USA.
This article is published under the
Creative Commons Attribution Noncommercial
License, which permits any non-commercial
use, distribution, adaptation and reproduction
provided the original author(s) and source are
given appropriate credit. © The Authors 2018.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 2004;27:2597–602.
Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. The Lancet. 2008;371:1753–60.
Carls G, Huynh J, Tuttle E, et al. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8:863–73.
Miller KM, Foster NC, Beck RW, et al. T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971–8.
Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillen V, Orozco-Beltran D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther Res TreatEduc Diabetes Rel Dis. 2013;4:175–94.
Silva DD, Bosco AA. An educational program for insulin self-adjustment associated with structured self-monitoring of blood glucose significantly improves glycemic control in patients with type 2 diabetes mellitus after 12 weeks: a randomized, controlled pilot study. Diabetol Metab Syndr. 2015;7:2.
Cypress M, Tomky D. Using self-monitoring of blood glucose in noninsulin-treated type 2 diabetes. Diabetes Spectrum. 2013;26:102–6.
Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. EndocrPract. 2008;14:750–6.
Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes: results of the HYPOS-1 study. Acta Diabetol. 2015;52:845–53.
Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015;41:116–25.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317:371–8.
Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63.
Riddlesworth T, Price D, Cohen N, Beck RW. Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabetes Ther. 2017;8:947–51.
Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, for the DIAMOND Study Group.Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138–46.
Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391:1367–77.
Ólafsdóttir AF, Polonsky WH, Bolinder J, et al. A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther. 2018;20:274–84.
Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–74
Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.
Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;61:539–50.
Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther. 2011;13:813–8.
Qu Y, Jacober S, Zhang Q, et al. Rate of hypoglycemia in insulin- treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14:1008–219.
Polonsky WH, Fisher L, Hessler D, Edelman SV. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol Ther. 2017;19:131–6.
Wild D, von Maltzahn R, Brohan E, et al. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10–5.
Haugstvedt A, Wentzel-Larsen T, Graue M, et al. Fear of hypoglycaemia in mothers and fathers of children with type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010;27:72–8.
Warren RE. Flash glucose monitoring: objective, not self-referential, outcomes are needed. Diabetologia. https://doi.org/10.1007/s00125-018-4608-0 (accessed 2 May 2018).
Bolinder J, Oskarsson P, Antuna R, et al. Flash glucose monitoring: objective, not self-referential, outcomes are needed. Reply to Warren RE [letter]. Diabetologia. https://doi.org/10.1007/s00125-018-4652-9. Accessed May 29, 2018.
Reddy M, Jugnee N, El Laboudi A, et al. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2018;35:483–90.
Khunti K, Alsifri S, Aronson R, et al. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Res Clin Pract. 2017;130:121–9.
Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange ClinicNetwork. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab. 2013;98:3411–9.
Cengiz E, Xing D, Wong JC, et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange Clinic Registry. Pediatr Diabetes. 2013;14: 447–54.
Akram K, Pedersen-Bjergaard U, Carstensen B, et al. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med. 2006;23:750–6.
Swediabkids Annual Report 2016. https://www.diabethics.com/forskning-teknik/swediabkids-2016/. Accessed May 23, 2018.
Unger J, Parkin CG. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med. 2011;123:81–91.
Kenny C. When hypoglycemia is not obvious: diagnosing and treating under-recognized and undisclosed hypoglycemia. Prim Care Diabetes. 2014;8:3–11.
Jauch-Chara K, Schultes B. Sleep and the response to hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2010;24:801–15.
Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26:1153–7.
Gomez AM, Gomez C, Aschner P, et al. Effects of performing morning versus afternoon exercise on glycemic control and hypoglycemia frequency in type 1 diabetes patients on sensor-augmented insulin pump therapy. J Diabetes Sci Technol. 2015;9:619–24.
The Diabetes Research in Children Network (DirecNet) Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes. J Pediatr. 2005;147:528–34
Weinstock RS, DuBose SN, Bergenstal RM, et al. Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. Diabetes Care. 2016;39;603–10.
Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513–7.
Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care. 2012;35:787–93.
Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013;36:3535–42.
Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–40.
Kalra S, Mukherjee JJ, Venkataraman S, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab. 2013;17:819–34.
4Noh RM, Graveling AJ, Frier BM. Medically minimising the impact of hypoglycemia in type 2 diabetes: a review. Expert Opin Pharmacother. 2011;12:2161–75.
Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. Can Med Assoc J. 2009;180:821–7.
Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes – the 'dead in bed' syndrome revisited. Diabetologia. 2009;52:42–5.
Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9:530–43.
Åsvold BO, Sand T, Hestad K, Bjørgaas MR. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia. Diabetes Care. 2010;33:1945–7.
Sundberg F Barnard K, Cato A, et al. ISPAD Guidelines. Managing diabetes in preschool children. Pediatr Diabetes. 2017;18:499–517.
Anderbro T, Amsberg S, Adamson U, et al. Fear of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2010;27:1151–8.
Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18:S42–S49.
Lowes L, Lyne P, Gregory JW. Childhood diabetes: parents' experience of home management and the first year following diagnosis. Diabet Med. 2004;21(6):531–8.
Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2004;350:2272–9.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.
Barnard K, Thomas S, Royle P, et al. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr. 2010;10:50.
Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281–90.
Bronstone A, Graham C. The potential cost implications of averting severe hypoglycemic events requiring hospitalization in high-risk adults with type 1 diabetes using real-time continuous glucose monitoring. J Diabetes Sci Technol. 2016;10:905–13.
Pawaskar M, Iglay K, Witt EA, et al. Impact of the severity of hypoglycemia on health – related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes. J Diabetes Comp. 2018;32(5):451–7.
Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665–71.
Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012;28:1947–58.
Polonsky WH, Fisher L, Hessler D. The impact of non-severe hypoglycemia on quality of life in patients with type 2 diabetes. J Diabetes Comp. 2018;32:373–8.
Wredling RA, Theorell PG, Roll HM, et al. Psychosocial state of patients with IDDM prone to recurrent episodes of severe hypoglycemia. Diabetes Care. 1992;15:518–21
Solli O, Stavem K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes. 2010;8:18.
Barnard K, James J, Kerr D, et al. Impact of chronic sleep disturbances for people living with T1 diabetes. J Diabetes Sci Technol. 2016;10:762–7.
Evans M, Khunti K, Mamdani M. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.
Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, et al. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, worktime loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;16:1453–61.
Adolfsson P, Parkin CG, Thomas A, Krinelke LG. Selecting the appropriate continuous glucose monitoring system – a practical approach. Euro Endocrinol. 2018;14:24–9.
US Food and Drug Administration. FreeStyle Libre Flash glucose monitoring system. Summary of Safety and Effectiveness Data (SSED). Available from https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160030B.pdf (accessed 21 January 2018).
Dexcom G6 continuous glucose monitoring systems user guide. https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf. Accessed June 2, 2018.
Dexcom, Inc. Dexcom G5 Mobile Safety Information. Available at https://www.dexcom.com/safety-information#dexcom-g5-mobile-safety-statement. (accessed 28 January 2018.)
US Food and Drug Administration. MiniMed 670G System. Summary of Safety and Effectiveness Data (SSED). Available from https://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017b.pdf (accessed 21 January 2018).
Christiansen MP, Klaff LJ, Brazg RR, et al. A prospective multicenter evaluation of the accuracy of a novel implanted continuous glucose sensor: PRECISE II. Diabetes Technol Ther. 2018;20:197–206.
Fokkert MJ, van Dijk PR, Edens MA, et al. Performance of the FreeStyle Libre Flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. BMJ Open Diabetes Res Care;5:e000320.
US Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED). Dexcom G4 PLATINUM Continuous Glucose Monitoring System. Available at: www.accessdata. fda.gov/cdrh_docs/pdf12/P120005S018b.pdf (accessed 3 December 2017).
Polonsky WH, Hessler D. Perceived accuracy in continuous glucose monitoring: understanding the impact on patients. J Diabetes Sci Technol. 2015;9:330–41.
Erie C, Van Name MA, Weyman K. Schooling diabetes: use of continuous glucose monitoring and remote monitors in the home and school settings. Pediatr Diabetes. 2018;19:92–7.
Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317:379–87.
Dover AR, Stimson RH, Zammitt NN, Gibb FW. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J Diabetes Sci Technol. 2017;11:442–3.
McKnight JA, Gibb FW. Flash glucose monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre. Diabet Med. 2017;34:732.
Ish-Shalom M, Wainstein J, Raz I, Mosenzon O. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016;10:1412–3.
Šoupal J, Petruželková L, Flekac M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. Diabetes Technol Ther. 2016;18:532–8.

redpajama_set_name: RedPajamaCommonCrawl


We will give you as much information on the setting that you are attending the interview with, however it is essential that you also do your own research and find out as much information about the organisation as possible, we recommend that you down load the latest Ofsted report and see how the setting has been performing, browse their website and familiarise yourself of the setting's background e.g. Are they a state or independent school, an independent nursery or part of a chain ? How many staff do they employ? How long have they been open for? What facilities and extra-curricular activities are offered? How many children attend the setting?
Make sure you really understand the EYFS – you will be asked questions on this in your interview in particular how you use it to support children's learning and development.
Anticipate questions around equal opportunity, safeguarding and how to support children with special needs.
It is really important that you look well presented. Hair should be neat, tidy and if long tied back. Jewellery should be kept to a minimum, studs not hoops for earrings, you may be asked to take part in a trial with the children so it is important that you dress in practical clothing so that you can plan and interact easily with the children. i.e. black trousers and flat shoes.
Make eye contact, speak clearly and smile.
Create a professional image and present your current CV, your original qualification certificates, DBS check, and other documents smartly in an appropriate document holder.
6. Plan you journey and arrive early.
To set the right first impression aim to arrive 15-20 minutes early.
Know how long it will take to get there, and where you will be able to park. If there is no parking at the setting, find out where the nearest car park is and make sure you allow enough to time to park and walk back to the nursery/school.
If you are travelling by public transport allow plenty of time, don't rely on the bus or train that gets in just in time as it may be late or cancelled. We suggest that you print off a map to take in case you get lost!
Never speak negatively about previous employers, children or agencies. This is absolutely essential as employers will always regard criticism and negativity as a flaw with the interviewee.
8. Prepare a list of questions you may ask at the end.
Q: How many children do you currently have in the Nursery/School how many are you registered for? Are there further plans to expand on this?
Q: Which room are you recruiting for and how many children are based in that room?
Q: Does the Nursery/School offer any training?
Q: Are there any chances for promotion in the Nursery/School?
Q: How does the Nursery/School work in partnership with parents and promote inclusion?
Q: When is a decision on my application likely to be made?
Although every interview is different there are a few questions that always pop up.
We have listed some on this page, we recommend that before you go to your interview, you have a look through and think about how you would answer them if asked.
The interviewer will want to see what you are really like and how you will fit into the team, preparing for the interview will enable you to demonstrate your knowledge and ensure that you get your personality across.
Why you left your previous position and what you are currently doing?
What is it you like about teaching or working in childcare?
Your strengths, achievements and development needs?
What are the seven areas of learning within the EYFS?
Your Subject knowledge, and current issues in your subject and education.
Are you flexible about working with any ages of children or do you have a preference of which age you like working with?
Give an example of an activity that worked well with children? How can this activity be changed for the different age groups.
How would you support a child who didn't speak English as a first language?
How could you support the needs of someone who has a disability?
Why is observing children playing important? If a child is being left out of a group activity what would you do? How would you get the other children to include them?
How would you set out a room in the morning?
Have you ever had any ideas about how things could work differently in your room and if so what were they and what changes were made?
If a child needs reminding about behaviour e.g. biting, hitting and kicking- how would you go about this?
How would you deal with disagreements amongst children in the classroom?
How would you establish and maintain relationships with parents or key interfacing groups?
What would you do if parent approached you about working for them directly?
What would you do if a child had an accident?
Your future plans and ambitions?
Please register your details now for a full career consultation or contact us for a confidential discussion.


text:
Obec Vračovice-Orlov se nachází v okrese Ústí nad Orlicí v Pardubickém kraji. Žije zde  obyvatel.

Historie
První písemná zmínka o obci pochází z roku 1349.

Části obce
 Orlov
 Vračovice

Reference

Externí odkazy

Vesnice v okrese Ústí nad Orlicí
Obce v Česku se složeným názvem
Obce v okrese Ústí nad Orlicí
Mikroregion Vysokomýtsko
Sídla ve Svitavské pahorkatině

redpajama_set_name: RedPajamaWikipedia


text:
FIL's Day — Sept. 19, 2021
Today was all about my father-in-law, Marvin. FIL died in November following complications from heart surgery and COVID. Wifey Poo and the sisters-in-law organized an ice cream social and issued an open invitation to the family and FIL's friends. When we set the date for late September, the thought was that we'd be past the hell that is Missourah summer. The 90 degrees and drink-the-air humidity we sweated through at Quail Ridge Park, Pavilion #3, laughed at our hubris.
We chose ice cream because FIL was always down for a bowl (or two). I always thought of ice cream as a warm-weather treat. FIL scoffed at that. We once had ice cream while in a barn during a raging January snowstorm. He had many favorite flavors. Moose tracks was up there. If it was available, his brother's homemade butter pecan bumped it down the list. It was available today, so I used my September cheat day from my new eating habits and had a bowl for FIL.
Softball Stories
FIL was an avid bicycle rider. He and his friends Don and Warren hit the Katy Trail, which crosses Missourah, at least weekly. Into his 70s, FIL routinely did 35 miles in a day with ease. I sat and talked with Don and Warren for a bit today. They were reminiscing about their slow-pitch softball glory days with precise recollections of plays in games that took place more than a half-century ago. "I always had one bone to pick with your father-in-law," Warren said. He recounted the 1968 league championship game in which his, Don's and FIL's team were tied in the last inning with a runner on third and one out. The batter hit a shot back up the middle. FIL, the team's pitcher, reached out to stop it, but it was just out of his reach and tipped off his glove. "I always gave him a hard time about it because if he'd just let it go through I was there at shortstop and it would have been an easy double play." As it went, everyone was safe and the go-ahead run scored.
The Swim Trunks
Wifey Poo was overjoyed to see her childhood best friend arrive. Julie and Wifey Poo go way, way, way back, to when Wifey Poo lived in North County, St. Louis. Julie came with a stack of old photographs featuring the two of them and their families. There was one picture from the old neighborhood in which FIL was manning the grill as various conversations took place around the yard. FIL was wearing a Hawaiian-print shirt and dark-blue swim trunks with white trim. I recognized those swim trunks. FIL wore them on the last float trip we went on as a family a few years ago. That put 30-plus years in between their appearances in the photo and my recent memory. That's so FIL. He took amazing care of everything he owned and was loath to throw out anything that had an ounce of life left in it.
The 'Don't Blame Me, I Didn't Say It' of the Day
'I want to punch him in the nuts.'
My 7-Year-Old nephew, Q, talking about a bully at his elementary school
Hostess with the Mostest
I spent much of the time at the ice cream social on the periphery, as I like to do. I enjoyed watching Wifey Poo as she bounced from conversation to conversation. She was so in her element. Wifey Poo is a social butterfly, and she's an amazing hostess. FIL would have been proud of her today.
My in-law family is pretty amazing.
Homemade butter pecan ice cream.
I bought a sound bar for the TV that comes tomorrow. Never had one before.


text:
Q: Problems to create a procedure in mysql raise error 1064 I have been looking for a solution for my query, I expended all of the day and I couldn't find an answer, I had tested my query normally and it worked, but when I put my code into a structure of a stored procedure to create a solution I always receive error code 1064.
This is the stored procedure I've been trying to create, can someone help me.
DELIMITER $$

CREATE
    PROCEDURE `ocomon_rc6`.`spGetChamadoMaisAntigo`(IN Sistema VARCHAR(MAX), IN CodigoUrl INT)
    BEGIN

    DROP TABLE IF EXISTS ocomon_rc6.TempChamados;

    CREATE TABLE IF NOT EXISTS ocomon_rc6.TempChamados(numero INT, dias_apos_abertura INT);

    INSERT INTO TempChamados(numero, dias_apos_abertura)
    SELECT
        o.numero,
        (CASE
            WHEN CONVERT(NOW(), TIME) > CONVERT(o.data_abertura, TIME) THEN DATEDIFF(NOW(), o.data_abertura)
            ELSE DATEDIFF(DATE_SUB(NOW(),INTERVAL 1 DAY), o.data_abertura)
        END CASE)
    FROM
        ocorrencias as o
    LEFT JOIN
        sistemas AS a ON
            a.sis_id = o.sistema
    LEFT JOIN
        sistemas_x_url AS su ON
            a.sis_id = su.sis_id
    LEFT JOIN
        urls ON
            su.codigoUrl = urls.codigoUrl
    LEFT JOIN
        localizacao AS l ON
            l.loc_id = o.local
    LEFT JOIN
        instituicao AS i ON
            i.inst_cod = o.instituicao
    LEFT JOIN
        usuarios AS u ON
            u.user_id = o.operador
    LEFT JOIN
        usuarios AS ua ON
            ua.user_id = o.aberto_por
    LEFT JOIN
        `status` AS s ON
            s.stat_id = o.status
    LEFT JOIN
        status_categ AS stc ON
            stc.stc_cod = s.stat_cat
    LEFT JOIN
        problemas AS p ON
            p.prob_id = o.problema
    LEFT JOIN
        sla_solucao AS sls ON
            sls.slas_cod = p.prob_sla
    LEFT JOIN
        prioridades AS pr ON
            pr.prior_cod = l.loc_prior
    LEFT JOIN
        sla_solucao AS slr ON
            slr.slas_cod = pr.prior_sla
    LEFT JOIN
        script_solution AS sol ON
            sol.script_cod = o.oco_script_sol
    LEFT JOIN
        prior_atend AS prioridade_atendimento ON
            prioridade_atendimento.pr_cod = o.oco_prior
    LEFT JOIN
        sistemas_x_filtro AS filtr ON
            filtr.codigoSistemaFiltro = o.filtro
    WHERE
        s.stat_painel IN (2)
    AND o.sistema IN (@Sistema)
    AND su.codigoUrl = @CodigoUrl
    AND o.oco_scheduled = 0
    ORDER BY
        o.data_abertura;

    SELECT * FROM TempChamados WHERE dias_apos_abertura = (SELECT MAX(dias_apos_abertura) FROM TempChamados);

    DROP TABLE IF EXISTS ocomon_rc6.TempChamados;

    END$$

DELIMITER ;

And this is the message of error I received
Error Code : 1064
You have an error in your SQL syntax; check the manual that corresponds to your MySQL server version for the right syntax to use near '@Sistema VARCHAR(MAX), @CodigoUrl INT)
    BEGIN

    DROP TABLE IF EXISTS ocomon_' at line 2

Execution Time : 00:00:00:000
Transfer Time  : 00:00:00:000
Total Time     : 00:00:00:000

A: VARCHAR(MAX) is not valid.  Try VARCHAR(255).

redpajama_set_name: RedPajamaStackExchange